Q-omics provides the consensus-scored CSF2RB profile across patient tissues and cancer cell-line models. CSF2RB expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, CSF2RB is differentially expressed in 10, with the highest sampling consensus in KIRC. Additionally, CSF2RB RNA expression shows 23,461 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight HNSC, KIRC, and LSCC as cancer lineages where CSF2RB shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CSF2RB — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CSF2RB survival associations across molecular data types. CSF2RB RNA expression shows survival associations in the most cancer types (27), followed by mutation status (12) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CSF2RB RNA expression–survival associations across cancer types. High CSF2RB expression shows unfavorable associations in LGG and UVM, but favorable associations in HNSC, LUAD, SKCM and CESC. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for CSF2RB RNA expression.
This table summarizes CSF2RB tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10, while mass-spec protein shows differences in 3. The strongest signals are observed in KIRC for RNA and PDAC for protein.
This table ranks reproducible tumor–normal expression differences for CSF2RB. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CSF2RB shows lower tumor expression in COAD, LUAD, LUSC, UCEC and KICH and higher tumor expression in KIRC. The KIRC box plot shows higher CSF2RB RNA expression in tumor versus normal tissue (log2 FC = +1.634, t-test p < 0.001).
This table shows molecular features associated with CSF2RB in patient tissues and cancer cell lines. In patient samples, CSF2RB shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, CSF2RB RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in OESOPHAGUS and BLOOD_Leukemia.
